Gail Garland, OBIO CEO talks with BNN about the economic and health benefits that accrue to Canada by building a globally competitive Canadian health science industry. Click here for the full interview.
Canada needs a strategy to reach its biotech potential
Ontario Bioscience Innovation Organization Announces Election of Shelley Boyd, Jeremy Bridge-Cook, Michael Cloutier and Cathy Szabo to its Board of Directors
Toronto, Ontario, November 4, 2015 – Ontario Bioscience Innovation Organization (“OBIO®”), a non-profit organization that is Ontario’s leading advocate for the life science sector, announces the election of four new members to its Board of Directors: Shelley Boyd, Jeremy Bridge-Cook, Michael Cloutier and Cathy Szabo.
Ontario Bioscience Innovation Organization Announces a Call for Applications for the 2016 Capital Access Advisory Program
Ontario Bioscience Innovation Organization Congratulates Ontario on the Appointment of Chief Health Innovation Strategist
Today, Ontario Bioscience Innovation Organization (OBIO®) released a statement congratulating the Government of Ontario on the appointment of William Charnetski as Ontario’s first Chief Health Innovation Strategist.
“OBIO congratulates Mr. Charnetski on his appointment to this pivotal role,” said Gail Garland, Chief Executive Officer of OBIO. “We look forward to supporting his efforts to catalyze adoption of innovative health technologies which strengthen the province’s capacity to deliver cost-effective, outcome-focused care for patients.”
OBIO Congratulates and Welcomes Johnson & Johnson Innovation, JLABS to the Ontario Bioscience Ecosystem
Toronto, Ontario, September 21, 2015 – The Ontario Bioscience Innovation Organization (OBIO®) is pleased to recognise Johnson & Johnson Innovation’s major contribution to Ontario’s human health bioscience ecosystem through the choice of Toronto as the first ex-US Johnson & Johnson Innovation, JLABS site. The JLABS incubator model is the highly successful creation of Johnson & Johnson Innovation and has been brought to Canada with the help of Janssen Inc. Known as JLABS @ Toronto, the site will join its fellow JLABS sites in San Diego, San Francisco, Boston and Houston.
Pre-Capital Access Advisory Program (Pre-CAAP)
OBIO Launches Pre-Capital Access Advisory Program (Pre-CAAP) – Builds on Successful Capital Access Advisory Program (CAAP™) Improving financing success of Ontario bioscience companies Toronto, Ontario, August 10, 2015 – Ontario Bioscience Innovation Organization (OBIO®) today announced the launch of the inaugural round of Pre-CAAP, a program in support of Ontario bioscience companies that aim to raise...
OBIO CAAP Program Receives FedDev Ontario Funding
Toronto, Ontario, May 22, 2015 – Ontario Bioscience Innovation Organization (OBIO®) today announced they have received an investment of up to $3.894 million from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) for OBIO®’s Capital Access Advisory Program (CAAP™).
“It is tremendous to see this practical support for commercializing health sciences and for building our human health bioscience industry,” said Gail Garland, President and CEO, OBIO®. “We are deeply grateful for this opportunity to expand our programming and help even more growing companies.”
2015 Healthcare Conferences
Click here for quick access to a list of 2015 Healthcare Conferences for industry and investors (member password required)
BioTransfer2014 – Toronto, March 18
Canadian excellence in research and technology Human health partnership opportunities For the next edition of BioTransfer2014, which will take place in Toronto on March 18, 2014, the most promising research and technology projects in the areas of therapeutics, diagnostics and health technologies will be presented. These projects represent over 32 partnership opportunities in various application areas, including cancer, cardiovascular disease and central nervous system disease, as well as integrated approaches such as personalized medicine.
BioTransfer2014 – Toronto will cover the following topics in human health:
- Biotherapeutics: promising candidates, R&D tools, biomarkers, companion diagnostics
- Diagnosis: R&D tools, biomarkers, companion diagnostic
- Medical technologies: invasive and non-invasive
Please note that Biotransfer2014 will now be held on Tuesday March 18, 2014 in Toronto at the Hyatt Regency Hotel.
Submit your technology!
Click here to event details online.
Why Healthcare Innovation Needs to be a Team Sport: Friday February 7
Join leading experts as they:
- Present the research undertaken to identify the enablers and barriers to innovation in Ontario’s healthcare environment
- Explore the recommendations required for successful scaling of innovation in Ontario’s health system, creating better outcomes for patients and the system
- Provide insights on how partnership and collaboration are necessary to make a positive impact on healthcare moving forward
Speakers: Robert Oliphant President and CEO of the Asthma Society of Canada
Gail Garland Chief Executive Officer, Ontario Bioscience Innovation Organization (OBIO®)
Dr. Robert Reid Deputy Chief of the Division of Prevention and Rehabilitation at the University of Ottawa Heart Institute
Moderator: Will Falk Managing Partner -Health Industries for PwC Canada and Executive Fellow at the Mowat Centre
Event Details: Friday, February 7, 2014 Breakfast: 7:30 a.m. - 9:00 a.m. Toronto Region Board of Trade Downtown Centre
Click here to view the event details.
Ontario’s Bioscience Cluster: Tapping the Untapped Potential
The OBIO® 2012 industry consultation and survey built on knowledge gained from OBIO’s previous three years of consultations. The financial health of Ontario’s industry hasn't changed significantly from prior years. Most companies are pre-revenue (50 percent) and 47 per cent have annual revenues of less than $10 million. Companies report their financial runway is approximately 14 months and the majority (82 per cent) of those who have raised capital (61 per cent) in the last year have raised less than $2 million. Research and development consumes 46 per cent of working capital followed by marketing and sales which accounts for 34 per cent. Patent costs, clinical trial costs and costs to raise capital consume the balance.
Rather than purely provide a ‘state of the industry’ update, this year’s consultation undertook to explore the sector’s potential in healthier conditions brought about through the reduction of uncertainty largely related to insufficient financial resources. With a nod to professor Michael Porter’s (Harvard University) work on cluster strength (Figure 1), OBIO asked industry leaders to weigh in on the quality of the business environment, access to specialized risk capital and depth within the domestic human health sciences private sector.
Specifically, the survey sought to gauge companies’ progress and expansion through the creation of new jobs and the impact on key projects’ time to commercialization. Additionally, the 2012 consultation survey set out to demonstrate the potential impact of the adoption of policies by the provincial government aimed at improving the quality of the business environment.
Survey results confirmed that most roadblocks and challenges facing biotech companies are related to uncertainty and insufficient funding. Industry’s feedback from 56 of 150 invitees was presented by David J. Pye, Ph.D at OBIO’s Annual General Meeting in November, 2012.
Click here to view the full article in PDF format.
Partnering to Win: Unlocking the Potential of International Conventions
Partnering to Win: Unlocking the Potential of International Conventions webinar is launched
TORONTO, May 2, 2012 – In today's global business environment, the importance of identifying and understanding the value proposition of international conferences and events has never been more important. Using the BIO International Convention as a case study, Betsy Bascom, CEO of Global Connectworks will discuss:
* Selecting the right international convention for your business development, investment or scientific goals
* Planning your experience from 'start to follow-up' for maximum results
* Connecting with your target list of business partners
* Using BIO's new Exhibitor Partnering program
Title: Partnering to Win: Unlocking the Potential of International Conventions
Date: Wednesday, May 2, 2012
Time: 3:00 PM - 4:00 PM EDT
Click here to download a PowerPoint version of the full webinar.
About OBIO
Ontario Bioscience Innovation Organization (OBIO™) is Ontario’s leading advocate for the life-science sector. A private sector, membership-based organization, OBIO engages in policy advocacy and government relations activities to enable successful development and commercialization of life-science technology through investment, strategic alliances, stakeholder engagement and industry promotion.
Further information, contact: Gail Garland, OBIO, at 416-575-7805 or gailgarland@obio.ca
Bioscience Industry Leaders Discuss Issues That Matter
On May 31, 2011 OBIO together with event sponsors, Sanofi, Torys, BDC and PWC hosted the Second Annual Quebec/Ontario Bioscience CEO dinner. The tradition started in 2010, to provide bioscience industry leadership with a unique opportunity to connect and discuss industry issues in a relaxed interacitve setting while enjoying a fine meal and refreshments. Building on last year’s positive word of mouth, the 2011 event was over-subscribed. This year, over 50 guests from across Canada came together at, ‘The Rosewater Supper Club’ in downtown Toronto for a cocktail reception before joining tablemates and embarking on the evening’s agenda.
The conversation was enriched by the perspectives of guests from British Columbia and Manitoba in addition to Québec and host province, Ontario. Attendees included industry leadership from therapeutic, device, diagnostic and healthcare IT companies, lawyers with sector and IP expertise; accountants with industry experience in programs such as SR&ED (Scientific Research and Experimental Development Tax Incentive Program) and financial and capital market executives.
Click here to read entire article